Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience

BACKGROUND: This retrospective study evaluates patient-reported outcomes in patients with multiple sclerosis (MS) spasticity who were treated with a cannabinoid oromucosal spray (Sativex®, USAN name: nabiximols) after not sufficiently responding to previous anti-spasticity medications. METHODS: Of 2...

Descripción completa

Detalles Bibliográficos
Autores principales: D’hooghe, Marie, Willekens, Barbara, Delvaux, Valerie, D’haeseleer, Miguel, Guillaume, Daniel, Laureys, Guy, Nagels, Guy, Vanderdonckt, Patrick, Van Pesch, Vincent, Popescu, Veronica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218396/
https://www.ncbi.nlm.nih.gov/pubmed/34157999
http://dx.doi.org/10.1186/s12883-021-02246-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218396/
https://www.ncbi.nlm.nih.gov/pubmed/34157999
http://dx.doi.org/10.1186/s12883-021-02246-0

Ejemplares similares